A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases

Leptomeningeal metastases (LM) are a severe complication of systemic cancer usually occurring in advanced stages which affect approximately 1 –10% of patients with solid tumors. [1–6] The incidence of LM (3–5%) in advanced NSCLC has increased over the last 10 years, especially in subgroups of patients with targetable mutations [6–8]. Although therapies such as molecular targeted treatments and immunotherapies have been described, standard treatment for LM is yet to be established [6,8–13].The median OS of lung cancer patients with LM is poor though with improvement from a historical 1–3 months to 3–11 months by modern systemic therapies [6,7,9].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research